| Identification | Back Directory | [Name]
(1α,1'S,4β)-Lanabecestat | [CAS]
1384082-96-5 | [Synonyms]
(1α
4β)-AZD3293
4β)-Lanabecestat
(1α,1'S,4β)-AZD3293
(1α,1'S,4β)-AZD3293
(1α,1'S,4β)-Lanabecestat
(1α,1'S,4β)-Lanabecestat
(1α,1'S,4β) Lanabecestat,(1α,1'S,4β)Lanabecestat | [Molecular Formula]
C26H28N4O | [MOL File]
1384082-96-5.mol | [Molecular Weight]
412.53 |
| Chemical Properties | Back Directory | [Boiling point ]
621.9±65.0 °C(Predicted) | [density ]
1.23±0.1 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMSO: 250 mg/mL (606.02 mM) | [form ]
Solid | [pka]
4.60±0.60(Predicted) | [color ]
Light yellow to khaki |
| Hazard Information | Back Directory | [Description]
(1α,1'S,4β)-Lanabecestat ((1α,1'S,4β)-AZD3293) is a Beta site APP Cleaving Enzymel (BACE1) inhibitor extracted from patent WO2012087237A1, compound 20a, has IC50s of 2.2 nM (TR-FRET assay) and 0.28 nM (sAPPp release assay), respectively[1]. | [Uses]
(1α,1'S,4β)-Lanabecestat ((1α,1'S,4β)-AZD3293) a less active enantiomer of Lanabecestat. Lanabecestat is a potent, orally active and blood-brain barrier penetrating BACE1 inhibitor with a Ki of 0.4 nM[1]. | [IC 50]
BACE1 | [References]
[1]. Gabor Csjernyik, et al. Compounds and their use as bace inhibitors. WO2012087237A1. |
|
|